Visible Particulate Contamination Control for Injectable Products: A Life-Cycle Approach

References

1. 1.↵
   1. Woodcock J.

   The Concept of Pharmaceutical Quality. Am. Pharm. Rev. 2004, 7 (6), 1–3.

   OpenUrl
2. 2.↵
   1. Langille S. E.

   Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   U.S. Pharmacopeial Convention, General Chapter <1> Injections and Implanted Drug Products (Parenterals) – Product Quality Tests. In USP 42–NF 37, USP: Rockville, MD, 2019.
4. 4.↵
   Council of Europe. Parenteral Preparations, Monograph 0520. In European Pharmacopoeia (Ph. Eur.), 9th Edition, Council of Europe: Strasbourg, France, 2018.
5. 5.↵
   Ministry of Health Labour and Welfare of Japan, General Tests, Process and Apparatus–6.06: Foreign Insoluble Matter Test for Injections. In The Japanese Pharmacopoeia, 17th Edition (English Version), MHLW: Tokyo, 2018.
6. 6.↵
   U.S. Pharmacopeial Convention, General Chapter <790> Visible Particulates in Injections. In USP 42–NF 37, USP: Rockville, MD, 2019.
7. 7.↵
   1. Wang H. S.

   Regulatory Perspective on Inspection of Injectable Products for Visible Particulates. Presented at PDA Visual Inspection Forum, Washington, DC, April 23, 2019.
8. 8.↵
   1. Taylor P.

   Top 5 Reasons for a Class I Product Recall. Pharmafile [Online] 2011. http://www.pharmafile.com/news/154814/top-5-reasons-class-i-product-recall (accessed Aug 2, 2019).
9. 9.↵
   Parenteral Drug Association Inc. Technical Report No. 79: Particulate Matter Control in Difficult to Inspect Parenterals; Bethesda, MD, 2018.
10. 10.↵
    1. Aldrich D. S.,
    2. Cherris R. T.,
    3. Shabushnig J. G.

    Visual Inspection and Particulate Control, 1st ed; Davis Healthcare International Publishing, LLC: River Grove, IL, 2016; pp 231–307.
11. 11.↵
    U.S. Pharmacopeial Convention, General Chapter <1790> Visible Inspection of Injections. In USP 41–NF 36, USP: Rockville, MD, 2018.
12. 12.↵
    International Conference for Harmonisation, Quality Guideline Q8: Pharmaceutical Development. ICH Geneva, 2005.
13. 13.↵
    U.S. Food and Drug Administration, Guidance for Industry: PAT–A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.
14. 14.↵
    GMP Question and Answers. World Health Organization Web Site. https://www.who.int/medicines/areas/quality_safety/quality_assurance/gmp/en/ (accessed July 10, 2019).
15. 15.↵
    U.S. Food and Drug Administration, Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2006.
16. 16.↵
    U.S. Food and Drug Administration, Guidance for Industry: Process Validation: General Principles and Practices. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
17. 17.↵
    European Medicines Agency, Guideline on the Sterilisation of the Medicinal Product, Active Substance, Excipient and Primary Container. EMA: London, 2019.
18. 18.
    U.S. Food and Drug Administration, 21 CFR Part 211--Current Good Manufacturing Practice for Finished Pharmaceuticals. U.S. Department of Health and Human Services, Government Publishing Office: Washington, D.C., 2019.
19. 19.
    Federal Food, Drug, and Cosmetic Act. U.S. Code, Sections 301-382, Title 21, 2019.